Stocktoria
FATE THERAPEUTICS INC FATE
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2013-10-01
FATE THERAPEUTICS INC statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating margin | -2222.4% | -1542.6% | -299.9% | -320.2% | -388.6% |
| Net margin | -2051.1% | -1366.5% | -253.3% | -292.5% | -379.9% |
| FCF margin | -1685.8% | -906.8% | -217.9% | -294.7% | -382.4% |
| Return on assets | -42.7% | -42.3% | -31.8% | -39.9% | -23.0% |
| Return on equity | -65.8% | -58.4% | -43.7% | -58.2% | -31.3% |
| Current ratio | 5.79 | 7.58 | 8.48 | 4.40 | 7.79 |
| Revenue growth | -51.2% | -78.5% | -34.0% | 72.4% | 77.7% |
Source: SEC EDGAR filings · CIK 0001434316 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.